



# Recombinant Rat Vascular Endothelial Growth Factor<sub>164</sub>



**FOR RESEARCH ONLY! NOT FOR HUMAN USE!**

<b>Cat.-no:</b>	<b>R20-067S</b>
<b>Size:</b>	2 µg
<b>Lot. No.:</b>	According to product label
<b>Country of origin:</b>	Germany

## Scientific Background

<b>Gene:</b>	<i>vegf</i>
<b>Synonyms:</b>	VEGF-A, VPF

Rat Vascular Endothelial Growth Factor<sub>164</sub> (VEGF<sub>164</sub>), a 19.23 kDa protein consisting of 164 amino acid residues, is produced as a homodimer. VEGF<sub>164</sub> is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. Two high-affinity tyrosine kinase receptors for VEGF<sub>164</sub> have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (Flk-1). Consistent with the endothelial cell-specific action of VEGF<sub>120</sub>, expression of both receptor genes has been found predominantly but not exclusively on endothelial cells. Expression of VEGFR-1 was also found on human monocytes, neutrophils (PMNs), bovine brain pericytes and villous and extravillous trophoblasts.

In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo and is also a chemo attractant for monocytes and endothelial cells. At least four different proteins are generated by differential splicing of the mouse VEGF gene: VEGF<sub>120</sub>, VEGF<sub>144</sub>, VEGF<sub>164</sub> and VEGF<sub>188</sub>. The most abundant form is VEGF<sub>164</sub>. Whereas VEGF<sub>120</sub>, VEGF<sub>144</sub> and VEGF<sub>164</sub> are secreted proteins, VEGF<sub>188</sub> is strongly cell-associated. In addition, the isoforms VEGF<sub>164</sub> and VEGF<sub>188</sub> bind to heparin with high affinity. All dimeric forms possess similar biological activities. A related protein of VEGF is placenta growth factor (PIGF) with about 53% homology and VEGF-B with similar biological activities.

The full ORF of native rat VEGF<sub>164</sub> (Ala27-Arg190) was cloned from total RNA of rat sinusoidal endothelial cells using standard protocols.

## References

1. Breier et al., Dev 114:521, 1992
2. Fiebig et al., Eur J Biochem 211:19, 1993
3. Flamme et al., Dev Biol 162:699, 1995
4. Kremer et al., Cancer Res 57:3852, 1997

## Sequence

APTTEGEQKSHEVIKFMVDVYQRSYCRPIETLVDIFQEY PDEIEYIFKPSCVPLMRCAGCCNDEALECVPTSESNITMQIMRIKPHQSQHIGEMSF LQHSRCECRPKKDRTPENHCEPCSERRKH L FVQDPQTCCKSCKN TDSRCKARQL ELNERTCRCDKPRR

## Database references

<b>Protein RefSeq:</b>	NP_114024.2.
<b>Uniprot ID:</b>	P16612
<b>mRNA RefSeq:</b>	NM_031836.2

## Product Specifications

<b>Expressed in</b>	E.coli
<b>Purity</b>	>95%, by SDS-PAGE and silver stain
<b>Buffer</b>	PBS
<b>Stabilizer</b>	None
<b>Formulation</b>	freeze dried
<b>Length (aa):</b>	164
<b>MW:</b>	19,23
<b>Result by N-terminal sequencing</b>	APTTEGEQKAH

**Stability:** Lyophilized samples are stable for greater than six months at -20°C to -70°C. Reconstituted VEGF<sub>164</sub> should be stored in working aliquots at -20°C.

**Reconstitution:** The lyophilized VEGF<sub>164</sub> should be reconstituted in ddH<sub>2</sub>O to a concentration not lower than 50µg/ml.




**AVOID REPEATED FREEZE AND THAW CYCLES!**

**Biological Activity:** Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 2-10 ng/ml.




# Recombinant Rat Vascular Endothelial Growth Factor<sub>164</sub>

## Handling/Applications



**Fig. 1:** SDS-PAGE analysis of recombinant rat VEGF<sub>164</sub>. Sample was loaded in 15% SDS-polyacrylamide gel under non-reducing conditions and stained with Silver stain.



**Fig. 2:** Stimulation of cell proliferation in primary human umbilical vein endothelial cells (HUVEC) by recombinant rat VEGF-A isoforms. Values are the means ( $\pm$ SD) of triplicate determinations and expressed as percentage of control.